Chemotherapy dosing in pediatric patient. Surapon Wiangnon Suddhavej Hospital Faculty of Medicine Mahasarakham University

Transcription

1 Chemotherapy dosing in pediatric patient Surapon Wiangnon Suddhavej Hospital Faculty of Medicine Mahasarakham University

2 Outline Principle of chemotherapy Use of BSA in chemotherapy dosing Pharmacokinetic consideration Chemotherapy dosing in special situation Carboplatin dosing using Calvert formula Obesity Amputees Down s syndrome Malnutrition Conclusion 2

3 Basic Principles of Cancer Therapy Cancer unregulated cellular proliferation Treatment modalities Surgery Radiation Drug therapy Treatment of choice for disseminated cancers, neoadjuvant 3

4 Obstacles to Successful Chemotherapy Toxicity to normal cells Absence of truly early detection Solid tumors respond poorly Limited drug access to tumor cells Heterogeneity of tumor cells Drug resistance 4

5 Strategies for Achieving Maximum Benefits from Chemotherapy Dose intensity Combination Maximum cell kill within acceptable toxicity Suppression of drug resistance Broad coverage against multiple cell lines Intermittent vs. continuous infusion Explain with cell cycle kinetics 5

6 Elsevier inc. item and derived items 2010 by saunders, an imprint of Elseveir Inc. 6

7 2012 American society of health system pharmacist 7

8 Principle of chemotherapy administration Non-Cell Phase Specific Agents Exert their cytotoxic effect throughout the cell cycle Cell kill is proportional to dose Cell Phase Specific Agents Toxic to the proportion of cells in the part of the cell cycle in which the agent is active Administer as a continuous infusion Begin therapy for kill resting cells, decrease tumor bulk, and recruit more cells into active division Follow with cell cycle-specific agents 8

9 Tumor growth kinetics Chemotherapy of benefit 9

10 Log kill kinetics Each course of chemotherapy kills a certain percent of cancer cell not number. Cytotoxic chemotherapy kills by 1st order kinetics Absolute zero: never reached Length of time between cycles: determined by the period of time it takes for normal tissues to rebound from drug toxicities 10

11 Optimizing dosing schedules Elsevier inc. item and derived items 2010 by saunders, an imprint of Elseveir Inc. 11

12 Dosing and Administration Based on the Patient s BSA Provides a more accurate estimate of crossspecies activity and toxicity May correlate with cardiac output and subsequent drug distribution and elimination 12

13 Body Surface Area Pinkel (1958) Retrospective analysis of therapeutic dose per unit weight vs. per unit BSA for 5 drugs Mechlorethamine, methotrexate, 6-mercaptopurine, actinomycin D, triethylene thiophosphoramide Similarity of the dosage per unit of BSA among animals and man Recommended BSA to be used for chemotherapy dosing Became the standard of dosing for chemotherapy until now 13 Cancer Res 1958;18:

14 Body Surface Area Which formula should we use? ASCO recommends any of the formula No evidence supporting one formula over another Mosteller formula: most commonly used Easy to use, remember J Clin Oncol ;30(13):

15 Body Surface Area No pharmacokinetic or efficacy studies to confirm Pinkel s findings Interpatient variability, in terms of pharmacokinetic parameters, still exist Physiological factors Intrinsic factors Environmental factors 15

16 The Oncologist 2007;12:

17 Body Surface Area Studies: correlation between PK of anticancer drugs and BSA of patient Clearance of several chemotherapy drugs were shown to be NOT correlated to BSA Eg. etoposide, ifosfamide, epirubicin, 5FU 17 Euro J Cancer 2002; 38;

18 Pediatric pharmacokinetic Children are not small adults The effects of chemotherapeutic agents on infants and young children are much different from those occurring in adolescents and adults Children differ from adults in each of the four pharmacokinetic stages 18

19 Pharmacokinetic considerations 4 PK stages: Absorption Distribution Metabolism Excretion 19

20 N Engl J Med 2003;349:

21 Ontogeny of Body Composition Premature Newborn 4 mo 12 mo 24 mo 36 mo Adult EC H 2 O IC H 2 O Protein Fat Other % of Total Body Weight Kaufman, Pediatric Pharmacology (Yaffe & Aranda, eds) pp , 1992

22 CNS Growth and Development 100 CNS Volume Adult Value [%] BSA Birth Age [yrs]

23 Acute Leukemia: Intrathecal dosage อาย (เด อน) Methotrexate (mg) Hydrocortisone (mg) Cytarabine (mg) <

24 Pediatric Chemotherapy Dosing In adults, dosing is usually based on BSA, a practice that is more historical than scientific Because of differences in PK properties, the chemotherapy dosage derived from adult studies may not accurately predict similar drug exposure in pediatric patients 24

25 Pediatric Chemotherapy Dosing When to use BW instead? Ratio of BSA to BW is significantly higher in infants and drastically lessens as a child grows Infants and young children, BSA can greatly overestimate the dose needed to achieve a desired AUC, whereas BW may be a more accurate predictor of drug exposure 25

26 Pediatric Chemotherapy Dosing Rule of 30 : used to adjust a dose from mg/m 2 to mg/kg (Pt with BSA of 1 m 2 weighs approximately 30 kg) This conversion can be problematic, since it sometimes leads to a large variability in calculated chemotherapy dose 26

27 Protocol name: ThaiPOG-HB-13LR Protocol for Low risk hepatoblastoma Drug Desired dose Route Day Total dose Cisplatin (CDDP) X 4 Cycles 80 mg/m 2 /dose IV drip in 24 hr mg/m 2 Give chemotherapy q 2 weeks, ANC > 1,000 and platelet > 100,000 before start chemotherapy Blood for LFT, AFP before each course and record liver size every course If BW < 12 kg, calculate chemotherapeutic agent dose per kg [(desired dose/ 30) xbw] G-CSF is not necessary, unless the patient has febrile neutropenia from the previous course 27

28 Pediatric Chemotherapy Dosing BSA-based dosing can be overestimated Different studies evaluating the same drug and tumor type may determine to use BWbased dosing in pediatric patients based on age (<12 months or <3 years) or weight (<10, 12, or 30 kg) 28

29 ThaiPOG-WT-1301: Favorable histology ความถ ต วยา ขนาดและว ธ ใช Day Cycle ท ก 3 wk ท ก 1 wk ท ก 3 wk Actinomycin-D Age < 12 months mg/kg IV Age 12 months mg/kg IV BW 30 kg 1.35 mg/m 2 IV (Maximum dose 2.3 mg) Vincristine1 Age < 12 months mg/kg IV Age 12 months 0.05 mg/kg IV BW 30 kg 1.5 mg/m 2 IV (Maximum dose 2 mg) Vincristine2 Age < 12 months mg/kg IV Age 12 months mg/kg IV BW 30 kg 2 mg/m 2 IV (Maximum dose 2 mg) 1 Wk 0, 3, 6, 9, 12, 15, 18 1 Wk Wk 12, 15, 18 29

30 Pediatric Chemotherapy Dosing In neonates, dose reductions of up to 50% are commonly made to offset the immaturity of elimination pathways Dose reductions are applied inconsistently across treatment regimens and protocols Often are based on toxicity observed in previous studies, rather than on true PK data 30

31 Carboplatin Cleared 70% by glomerular filtration Carboplatin plasma clearance is linearly related to GFR Clearance of Carboplatin correlates better with AUC than with BSA J Clin Oncol 1989;7:

32 Carboplatin Dosing Formula based on renal function is derived Dose (mg) = target AUC x (GFR + 25) AUC correlates with thrombocytopenic nadir AUC of 4-6 for 3 weekly regimen gave rise to manageable hematological toxicity AUC of 2 for weekly regimen J Clin Oncol 1989;7:

33 FDA dose capping recommendations GFR used in calvert formula should not exceed 125ml/min AUC 6 = 900 mg AUC 5 = 750 mg AUC 4 = 600 mg Dosing above the FDA dose capping recommendations is rarely seen with the above dosing recommendations 33

34 Dosing chemotherapy in obesity Use of actual body weight for dosing chemotherapy Crucial when treatment goal is to cure No evidence of increased short-or long-term toxicity Myelosuppression is the same or less in obese patients with cancer than in non-obese patients Reduced doses may result in poorer disease-free and overall survival rates 34

35 Dosing chemotherapy in obesity Use actual body weight (ABW) in calculating chemotherapy dose regardless of obesity status for oral and intravenous routes Cap the Vincristine to a maximum of 2 mg in CHOP and CVP Cap Bleomycin in BEP 35

36 Dosing chemotherapy in amputees Drug distribution Change in body composition Size of vascular system Cardiac output may change Drug metabolism Unlikely to change Drug excretion Unlikely to change 36

37 Dosing chemotherapy in amputees Different methods, so confer with protocol guidelines Use original weight and height prior to amputation to calculate BSA Use post-surgical weight and original height to calculate BSA 37

38 Dosing chemotherapy in amputees Am J Hosp Pharm 1984: 41:

39 Protocol ThaiPOG-OS-18-MTX Drug Dose Route A: Doxorubicin 37.5 mg/m 2 /day IV x 2 days (IV slowly push) P: Cisplatin 60 mg/m 2 /day IV over 6 hours x 2 days M: HD MTX 12 gm/m 2 /day IV over 4 hour (max 20 gm) Leucovorin 15 mg/m 2 /dose IV q 6 h, starting at hr 24 of MTX infusion ( > 8 doses) การร กษา osteosarcoma ผ ป วยจะได ร บยา neoadjuvant chemotherapy เพ อลด ขนาดของก อนเน องอกและด การตอบสนองของก อนเน องอกต อยาเคม บาบ ด ซ งเป น prognostic factor หน ง และยาเคม บาบ ดสามารถควบค มเน องอกท metastasis หล งการผ าต ดผ ป วยจะได ร บ adjuvant chemotherapy ต ออ กระยะ Amputee chemotherapy dosage (ThaiPOG): 39

40 Down s syndrome Down syndrome or constitutional trisomy 21 Linked to leukemia Trisomy 21 likely contributes to the development of GATA1 mutations Chromosome 21-localized genes Cystathionine-β- synthase (CBS) Zinc-copper superoxide dismutase(sod1) Folate metabolism 40

41 Down s syndrome Effect Impaired cytidine deaminase activity Increased superoxide dismutase (SOD) activity Impaired carbonyl reductase 1 (CBR1) activity Increased reduced folate carrier(slc19a1) 41

42 Down s syndrome Treatment-related toxicity: more frequent and severe Treated with corticosteroids: increased risk of developing hyperglycemia May consider decrease the dose or closely monitor toxicity from therapy 42

43 Protocol name: ThaiPOG-AML-DS Reference: COG AAML0431 Protocol for: AML-DS Drug Route Dosage Days Cytarabine (ARA-C) IV continuous 200 mg/m 2 /day or 6.67 mg/kg/day if age < 36 mo Doxorubicin (DOX) IV continuous 20 mg/m 2 /day or 0.67 mg/kg/day if age < 36 mo Thioguanine (6TG) PO 50 mg/m2/dose PO BID 1.65 mg/kg/dose PO BID if age < 36 mo Days 1-4 Days 1-4 Days 1-4 Intrathecal Cytarabine (IT ARA-C) IT Age (mo) < ARA-C 20 mg 30 mg 50 mg 70 mg Day 1 Note # For CNS 3 patient: give twice weekly IT cytarabine until CNS is clear for 2 consecutive times. Patient with refractory CNS leukemia following 6 doses of therapy will be managed according to institutional protocol หากสถาบ นใดไม ม 6TG สามารถต ด 6TG ออกได โดยให แค เพ ยง cytarabine และ doxorubicin 43

44 Special consideration There was a significant relationship between the prevalence of treatment-induced neutropenia and malnutrition (South African J Clin Nutr 2017) Malnourish patient: BW < 12 kg, chemo dose 2/3

45 Protocol name: ThaiPOG-HOD-1801 Reference: COG AHOD 0431 Protocol for: Low Risk Hodgkin Disease Drug Route Dosage Days Doxorubicin (DOX) IV push over 5 minutes 25 mg/m 2 /dose 1, 2 Bleomycin (BLEO) IV over 10 minutes 5 Units/m 2 /dose 10 Units/m 2 /dose* 1 8* Vincristine (VCR) IV push over 1 minute 1.4 mg/m 2 /dose** 1, 8 Etoposide (ETOP) IV over 1-2 hours 125 mg/m 2 /dose 1, 2, 3 **Max dose for vincristine 2.8 mg/dose 45

46 Conclusion Dose based on BSA may not be the best method for every drug Use actual body weight to dose chemotherapy for obese patients There is a lack of evidence and guideline for dosing of chemotherapy in amputees However, based on the theoretical PK of drugs in amputees and the intention of cure, not unreasonable to use pre-amputation weight and height 46

47 Conclusion Multiple factors complicate the treatment of cancer in pediatric patients Clinicians must take these many factors into account when designing chemotherapy regimens for pediatric patients Ultimately, these considerations will enable better care and monitoring of pediatric patients with cancer 47